Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
- EligibilityCriteria: Inclusion Criteria:  History of cardiovascular (CV) disease, high CV risk, or estimated glomerular filtration rate (eGFR) ≥30 to <60 mL/min/1.73m^2 Mean seated office SBP ≥140 mmHg and ≤170 mmHg 24-hour mean SBP ≥130 mmHg and ≤170 mmHg assessed by ABPM Must be on stable therapy with 2 to 4 classes of antihypertensive medications  Exclusion Criteria:  Secondary hypertension Orthostatic hypotension Proteinuria >3 g/day Serum potassium >4.8 mEq/L - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult